What is LOPJLB’s current signal on SABS?

LOPJLB’s latest quantitative signal on SAB Biotherapeutics, Inc. (SABS) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is SABS in?

SAB Biotherapeutics, Inc. (SABS) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does SAB Biotherapeutics, Inc. (SABS) do?

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabete…

Where is SAB Biotherapeutics, Inc. based / listed?

SAB Biotherapeutics, Inc. is based in US, listed on NASDAQ.

SAB Biotherapeutics, Inc. (SABS)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$2.98+3.11%Close

SELLCRISIS · day 11

[SCORES & PROFILE]

FUND: 16
VALUE: 20
GROWTH: 47
GARP: 5
TYPE: Balanced

Composite of Value · Growth · GARP

ROIC-4.0%

REV YoY-

ROE-6.7%

EPS YoY-

ROA-5.4%

GROSS

NET

[VALUATION]

P/E TTM0.82

P/E FWD-

SECTOR PE20.47

INDUSTRY PE13.95

P/B1.09

P/FCF-

EV/EBITDA-27.84

EV/EBIT-

PEG-

FCF YIELD-

RISK

INT COV-

D/E2.39

ALTMAN Z-

CURR RATIO9.22

ND/EBITDA-

BETA0.58

SAB Biotherapeutics, Inc. (SABS)

Key stats

Prediction markets

FUNDAMENTALS

Company news